Physician profile
Caitlin E Herbener
NPI 1609204684
$3,515.84
in general payments reported to CMS, 2019-2025
23 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $790 · 2023: $972 · 2024: $633 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $615.54 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $537.66 | 2021-2024 | Camzyos, Eliquis |
| Pfizer INC. | $372.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.81 | 2021-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $242.55 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $191.52 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $178.81 | 2023-2024 | Optimizer, Optimizer |
| Heartflow, INC. | $160.95 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $149.42 | 2023-2025 | Verquvo, Winrevair, Belsomra |
| Janssen Pharmaceuticals, INC | $111.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.28 | 2021-2023 | |
| Kestra Medical Technology Services, INC. | $98.60 | 2024-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.20 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $74.85 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.28 | 2023-2025 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $52.21 | 2025 | |
| United Therapeutics Corporation | $39.36 | 2021-2024 | Orenitram, Tyvaso, Remodulin |
| Scpharmaceuticals INC. | $30.73 | 2023 | |
| Akcea Therapeutics, INC. | $23.16 | 2021 | |
| Cvrx, INC. | $21.43 | 2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $18.01 | 2023 | Injectafer |
| Boston Scientific Corporation | $17.05 | 2024 | Watchman Flx |
| Novo Nordisk INC | $15.61 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Herbener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.